Guillaume Rémy advised the funders and the company in the context of a series A financing round of €1 million by Brainvectis, a company specialized in gene therapy for neurodegenerative diseases, specifically Alzheimer’s and Huntington’s diseases, today announces that it has closed a series A financing round of €1 million from private investors. The funds will allow the company to complete preclinical pharmacological tests in order to enter into the clinical trial phase in 2019 for Huntington’s disease, and in 2021 for Alzheimer’s disease.
